Lioton (Heparin Sodium)

Heparin sodium enhances the activity of antithrombin III, a protein that naturally inhibits clotting enzymes. By accelerating the inactivation of thrombin and factor Xa, it prevents the conversion of fibrinogen to fibrin, thereby limiting clot development at the site where the product is applied.

The specific amount and frequency of Lioton application are determined by the prescribing health professional based on the individual’s condition, the size of the area to be treated, and local practice guidelines. Patients should follow the prescriber’s instructions and not exceed the recommended usage.

The safety of topical heparin sodium during pregnancy and lactation has not been definitively established. Health care providers usually weigh the potential benefits against any unknown risks before recommending use in pregnant or nursing individuals.

To place an order, submit an enquiry on the Lioton product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with systemic anticoagulants, Lioton provides a localized effect with minimal systemic exposure, making it suitable for superficial conditions. Unlike oral agents, it does not require systemic monitoring of coagulation parameters, but it may be less effective for deep or extensive thrombotic events where systemic therapy is indicated.

Lioton should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight and excessive heat. Ensure the packaging is sealed when not in use to maintain product integrity.

Lioton is applied topically to clean, dry skin. A thin layer is spread over the affected area, usually 1–2 times daily, or as directed by a health professional. Avoid applying to open wounds, mucous membranes or broken skin unless specifically instructed.

The most serious risks include severe allergic reactions such as anaphylaxis, systemic anticoagulation leading to unexpected bleeding, and heparin‑induced thrombocytopenia (HIT), a rare immune‑mediated drop in platelet count. Patients should seek immediate medical attention if they notice signs of severe bleeding or allergic response.

Lioton should not be used by individuals with a known allergy to heparin or any of its excipients, patients with active bleeding disorders, those with open wounds or large skin abrasions at the intended site, and pregnant or breastfeeding women unless the prescriber determines that the benefits outweigh potential risks.